St. Jude pacing
This article was originally published in The Gray Sheet
New comorbidity indications, including syncopy and sleep apnea, are among the enhancements St. Jude hopes to add to its line of AF-suppressing, low-voltage bradycardia systems, the company tells investors during its Q1 earnings call April 17. The development is one of several initiatives to be discussed at the firm's May 1-2 analyst meeting in Minnesota. St. Jude also will discuss the launch of a porcine stented tissue valve in 2003 and may also provide further detail on the VecTor trial of the EPIC HF high-voltage resynchronization system, which is expected to gain PMA approval in 2003...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.